The primary endpoint for all the SURPASS trials was the change in HbA1c from baseline. The mean reductions in HbA1c ranged from 1.7% to 2.4% across all the SURPASS trials and varied according to ...
Summit Therapeutics plc (NASDAQ:SMMT) shares, currently trading at $19.03, maintained its Buy rating and $44.00 price target ...
Hosted on MSN1mon
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointmentSince Ozempic blasted onto the stage in 2017 with its approval for type 2 diabetes ... but didn’t cleanly surpass it in late-stage clinical trial findings reported Friday.
Korea Joongang Daily on MSN8d
Vehicle registrations surpass 26 mil. units; eco-friendly cars exceed 10 %up 2.2 percentage points on-year to surpass the 10 percent threshold for the first time. In contrast, the total number of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback